The peripheral vascular devices market is expected to grow at a CAGR of 6.9% from 2021 to 2028 to reach $12.02 billion by 2028.
The growing prevalence of vascular diseases, increasing prevalence of secondary risk factors associated with the development of vascular diseases such as diabetes, obesity, disease-causing lifestyles, and old age, and the rising demand for minimally invasive treatment procedures are the factors driving the growth of peripheral vascular devices market.
Here are the top 10 companies operating in peripheral vascular devices market
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a comprehensive range of health technologies and products. The company offers a wide range of diagnostics, medical devices, nutritional, and pharmaceutical products to meet customers’ needs. The company operates through four reportable business segments, namely Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers its peripheral vascular devices products through its Vascular subsegment under its Medical Devices business segment.
The company has a wide geographic presence in countries such as the U.S., China, Germany, Japan, India, Switzerland, and the Netherlands. The company operates through 92 manufacturing facilities located across the globe, of which 23 facilities are dedicated to developing diagnostic products. The subsidiaries of the company operating in the peripheral vascular devices market are Abbott Cardiovascular Systems Inc. (U.S.), Abbott Vascular Inc. (U.S.), Abbott Vascular Solutions Inc. (U.S.), Integrated Vascular Systems, Inc. (U.S.), Abbott Vascular International BVBA (Belgium), Abbott Vascular Deutschland GmbH (Germany), Abbott Vascular Devices Ireland Limited (Ireland), Abbott Vascular Knoll-Ravizza S.p.A (Italy), Abbott Vascular Japan Co., Ltd (Japan), Abbott Vascular Devices Holland B.V. (Netherlands), and Abbott Vascular Devices Limited (United Kingdom), among others.
B. Braun Melsungen AG
B. Braun Melsungen AG is engaged in manufacturing, marketing, and selling products and services for basic medical care, intensive care units, anesthesia and emergency care, extracorporeal blood treatment, and core surgical procedures globally. The company provides a range of products and solutions for infusion, nutrition and pain therapy, infusion pumps and systems, disinfection products, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories for extracorporeal blood treatment, as well as products for ostomy care, and diabetes and wound management. The company operates through four reportable business segments, namely, B.Braun Hospital Care, B.Braun Aesculap, B.Braun Out Patient Market, and B.Braun Avitum. The company offers products for the peripheral vascular devices market through its B.Braun Aesculap business segment.
B. Braun Melsungen AG has a wide geographic presence in over 64 countries in Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa. The company has its major manufacturing facilities in Europe, Switzerland, the U.S., Brazil, Vietnam, and Malaysia and distributes its products all over the globe via a network of subsidiaries and associated companies. The subsidiaries of the company operating in the peripheral vascular devices market are AESCULAP AG (Germany), Aesculap Chifa Sp. z o.o., Nowy (Poland), Aesculap SAS, Chaumont (France), Aesculap Inc., (U.S.), Aesculap Implant Systems LLC (U.S.), B. Braun Aesculap Japan Co Ltd (Japan), and B. Braun Aesculap de México S.A. de C.V. (Mexico), among others.
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a global medical technology company involved in medical research and genomics, enhancing infectious disease and cancer diagnosis, improving medication management, promoting infection prevention, equipping surgical and interventional procedures, and supporting diabetes management. The company is engaged in the development, manufacture, and sale of various medical supplies, devices, laboratory equipment, and diagnostic products. Becton, Dickinson and Company primarily operates through three business segments, namely BD Medical, BD Life Sciences, and BD Interventional. The company provides peripheral vascular devices through its Peripheral Intervention unit under the BD Interventional business segment. The company’s primary customers served by the BD Interventional segment are hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities.
BD manufactures and sells its products in the U.S., Europe, the Middle East, Greater Asia, Latin America, and Canada. BD has manufacturing operations outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, the Dominican Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, and the U.K. The company has a wide global distribution network that markets its products through independent distribution channels and directly to hospitals, other healthcare institutions, and independent sales representatives. Some of the major subsidiaries of the company are Bard Access Systems, Inc. (U.S.), Bard Canada Inc (Canada), Bard (Thailand) Limited (Thailand), Bard Australia Pty. Limited (Australia), Bard Benelux N.V. (Belgium), Bard de Espana, S.A. (Spain), Bard European Distribution Center N.V. (Belgium), Bard Holding GmbH & Co. KG (Germany), Bard Hong Kong Limited (China), Bard Norden AB (Sweden), Bard Singapore Private Limited (Singapore), Becton Dickinson India Private Limited (India), and Becton Dickinson Italia S.p.A. (Italy).
Koninklijke Philips N.V.
Koninklijke Philips N.V. is a health technology company involved in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, consumer health, and home care. The company operates through four reportable segments, namely Diagnosis & Treatment Business, Connected Care Business, Personal Health Business, and Other. The company provides peripheral vascular devices through its Diagnosis & Treatment Business segment.
The company operates through 17 Market organizations that are active in more than 100 countries worldwide. The company has 35,640 employees working in 35 manufacturing sites globally. The company has established subsidiaries in over 80 countries. The major subsidiaries of the company operating in the peripheral vascular devices market are Philips Medical Systems Ltda. (Brazil), Philips (Jiaxing) Health and Technology Co., Ltd. (China), Philips Healthcare (Suzhou) Co., Ltd. (China), Philips Medical Systems DMC GmbH (Germany), Philips Medical Systems Technologies Ltd. (Israel), Volcano Israel Holdings Ltd. (Israel), VitalHealth Care B.V. (Netherlands), Volcano Netherlands Holdings B.V. (Netherlands), Philips Medical Systems Puerto Rico, Inc. (Puerto Rico), Volcano Therapeutics South Africa Pty Ltd (South Africa), and Volcano Corporation (U.S.) among others.
Biotronik SE & Co. KG
Founded in 1963 and headquartered in Berlin, Germany, Biotronik SE & Co. KG is a privately held medical devices company. The company is engaged in developing, manufacturing, and selling medical devices and equipment for the diagnosis and treatment of cardiovascular and endovascular diseases. The company provides a wide range of products and services for cardiac rhythm management, vascular intervention, and electrophysiology. The company offers products for the peripheral vascular devices market through its peripheral vascular intervention portfolio.
Biotronik SE & Co. KG has a global presence in more than 100 countries across Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa. The company has manufacturing facilities in Germany, Switzerland, the U.S., and Singapore, with over a thousand employees worldwide. The subsidiaries of the company operating in the peripheral vascular devices market are BIOTRONIK, Inc. (U.S.), BIOTRONIK Canada Inc. (Canada), BIOTRONIK France S.A.S. (France), BIOTRONIK ITALIA S.p.A. (Italy), BIOTRONIK SPAIN S.A. (Spain), BIOTRONIK UK Ltd. (U.K.), BIOTRONIK (Beijing) Medical Device Ltd (China), BIOTRONIK Medical Devices India Private Ltd. (India), BIOTRONIK Japan, Inc. (Japan), and BIOTRONIK Asia Pacific Pte Ltd (Singapore), among others.
A report into the projected growth of the current Peripheral Vascular Devices Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2028, it’s expected to have grown at a CAGR of 6.9%, reaching over $12.02 billion.
Boston Scientific Corporation
Boston Scientific Corporation is engaged in the development, manufacture, and marketing of a broad range of medical devices. The company provides products and solutions in the fields of endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management, urology, and pelvic health. The company operates through three reportable business segments, namely MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers its peripheral vascular devices through its Peripheral Interventions operating subsegment under the Cardiovascular business segment.
Boston Scientific Corporation has a global geographic presence in regions such as the U.S., Europe, the Middle East, Africa, Asia-Pacific, Latin America, and Canada. The company operates through 5 headquarters and 12 manufacturing and R&D facilities located all across the globe. The subsidiaries of the company operating in the peripheral vascular devices market are Boston Scientific (U.K.) Limited (England), Boston Scientific AG (Switzerland), Boston Scientific Argentina S.A. (Argentina), Boston Scientific Asia Pacific Pte. Ltd. (Singapore), Boston Scientific Benelux NV (Belgium), Boston Scientific Canada Limited (Canada), Boston Scientific Ceskarepublika s.r.o. (Czech Republic), Boston Scientific Chile SpA (Chile), Boston Scientific Clonmel Limited, in liquidation (Ireland), BSC Medical Device Technology (Shanghai) Co., Ltd. (China), and BTG International Inc. (U.S.), among others.
Cardinal Health, Inc.
Cardinal Health, Inc. is primarily engaged in the development, manufacture, and supply of pharmaceuticals and medical products for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two reportable business segments, namely the Pharmaceutical segment and the Medical segment. Peripheral vascular devices are offered by the company’s subsidiary, Cordis Corporation, through the Medical business segment. Cordis Corporation was founded in 1957 and acquired by Cardinal Health in 2015. Cordis Corporation develops and manufactures medical devices for interventional and diagnostic procedures.
The company has a wide geographic presence in the U.S., Canada, Europe, Asia, and other markets across the globe. The subsidiaries of the company operating in the peripheral vascular devices market are Cordis Corporation (U.S.), Cordis Cashel Company Unlimited (Ireland), Cordis (Shanghai), and Medical Devices Co., Ltd. (China).
Medtronic Public Limited Company is engaged in the research, design, manufacturing, and sales of a wide range of device-based medical therapies and services. The company operates through four reportable business segments, namely the Cardiac and Vascular Group, the Minimally Invasive Therapies Group, the Restorative Therapies Group, and the Diabetes Group. The company provides peripheral vascular devices products through the Cardiac and Vascular Group business segment. The Aortic, Peripheral & Venous division of this segment provides products for treating aortic disease, peripheral vascular disease, and venous disease. The company’s primary customers are hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including government healthcare programs and group purchasing organizations.
The company operates in more than 150 countries all over the globe. The company’s principal executive office is located in Dublin, Ireland, while its operational office is located in Minnesota, U.S. The company has manufacturing and research facilities in countries such as the U.S., China, Puerto Rico, Mexico, Italy, Ireland, Switzerland, and Israel.
Founded in 1963 and headquartered in Indiana, U.S. Cook Group offers a diverse portfolio that includes medical devices, building materials, manufacturing, plastic, packaging, and containers. The company’s major subsidiary, Cook Medical, is involved in the development, manufacture, and sale of various medical devices. Cook Medical has two major divisions, namely, Vascular and MedSurg. The Vascular division offers products for the peripheral vascular devices market.
Cook Medical offers its products across 135 countries globally. The Cook Group has more than 12,000 employees worldwide. The subsidiaries of Cook Group are Cook Medical, Cook Properties, Cook Services, and Cook Brothers Insulation, among which only Cook Medical operates in the peripheral vascular devices market.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is focused on medical innovation for developing, manufacturing, and offering products to treat advanced cardiovascular disease. The company provides a wide range of products for heart valve therapy, critical care, cardiac surgery systems, and vascular diseases. The company operates through four reportable business segments, namely Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Heart Valve Therapy, and Critical Care. The company offers peripheral vascular devices products through its Critical Care segment.
The company has a wide geographic presence, majorly in the U.S., Europe, and Japan, and has seven manufacturing sites globally. The company’s major subsidiaries are Edwards Lifesciences LLC (U.S.), Edwards Lifesciences LLC (Germany), Edwards Lifesciences (Japan) Limited, Edwards Lifesciences Holding B.V. (Netherlands), and Edwards Lifesciences AG (Switzerland), among others.
Popular Mentions: NIPRO CORPORATION, IVASCULAR S.L.U, TERUMO CORPORATION, BLUE SAIL MEDICAL CO., LTD, TE CONNECTIVITY LTD.
Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/download-sample-report/cp_id=5180
Authoritative Research on the Microfluidic Immunoassay Market – Global Opportunity Analysis and Industry Forecast (2019-2025)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- The Impact of COVID-19 on the Peripheral Vascular Devices Market
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: